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ABSTRACT
Epigallocatechin-3-gallate (EGCG) is a naturally derived compound from green tea with high antioxidant activity and 
various anti-cancer properties. EGCG has been widely investigated worldwide. However, effects of EGCG on cell cycle 
of K562 have not been clearly stated elsewhere. This study was conducted with the aim to investigate the antiproliferative 
effect of EGCG on K562 human leukemic cells and its underlying mechanism of action on the cells. MTT assay was 
conducted to determine cytotoxicity effect of EGCG on the K562 cells. Meanwhile, cell cycle analysis and DNA damage 
on the cells were determined by Flow cytometry and Comet assay respectively. K562 cells were treated with EGCG at 
concentrations ranging from 0 to 100µg/ml for 48 hours. The results showed that EGCG effectively decreased the 
percentage of cell viability in a dose dependent manner. The IC
10
, IC
25
 and IC
50
 of EGCG on K562 cell lines were 5 ± 2.44 
µg/mL, 10 ± 5.93 µg/mL and 50 ± 1.93 µg/mL, respectively. In cell cycle assay, EGCG has shown no significant effect 
(p>0.05) on the cell cycle of K562 cell line as compared to negative control, whereas Imatinib mesylate as the positive 
control showed cell cycle arrest at S phase in this cell line. Hence, EGCG can be verified as a non-cell cycle specific 
compound. In addition, EGCG was found to cause a significant increase (p<0.05) in tail moment value and percentage 
of DNA tail in K562 cell line, suggesting DNA damage as an early signal of EGCG induced cell cytotoxicity. In conclusion, 
by decreasing the cell viability and inducing DNA damage, EGCG showed promising potential as an alternative treatment 
for leukemia through non-cell cycle specific pathway and further investigation on other mechanisms of action of EGCG 
on the cells is recommended.
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ABSTRAK
Epigallocatechin-3-gallate (EGCG) adalah sebatian yang berasal dari teh hijau yang kaya dengan aktiviti antioksidan 
dan pelbagai ciri anti-kanser. Kajian terhadap EGCG telah banyak dijalankan di seluruh dunia. Walau bagaimanapun, 
kesan EGCG pada kitar sel K562 masih belum dikaji dengan jelas. Kajian ini dijalankan bertujuan untuk mengenalpasti 
kesan antiproliferasi EGCG pada sel leukemia manusia K562 dan mekanisma tindakannya terhadap sel tersebut. Ujian 
MTT dijalankan untuk menentukan kesan sitotoksik EGCG terhadap sel K562, manakala analisis kitaran sel dan 
kerosakan DNA pada sel tersebut ditentukan menggunakan sitometri aliran dan asai Comet. Sel K562 dirawat EGCG 
pada kepekatan di antara 0 hingga 100 μg/mL selama 48 jam. Hasil kajian menunjukkan bahawa EGCG berkesan 
menurunkan peratusan viabiliti sel secara bergantung dos. Nilai IC
10
, IC
25
 dan IC
50
 EGCG pada sel K562 adalah 5 ± 2.44 
μg/mL, 10 ± 5.93 μg/mL dan 50 ± 1.93 μg/mL masing-masing. Dalam ujian kitaran sel, EGCG tidak menunjukkan kesan 
yang signifikan (p> 0.05) pada kitaran sel K562 sel berbanding dengan kawalan negatif. Manakala Imatinib mesylate 
sebagai kawalan positif menunjukkan pemerangkapan kitaran sel pada fasa S dalam sel kajian. Oleh demikian, EGCG 
boleh disahkan sebagai sebatian khusus tidak mengganggu kitaran sel. Tambahan lagi, EGCG didapati menyebabkan 
peningkatan signifikan (p<0.05) pada nilai momen ekor dan peratusan ekor DNA dalam sel K562, yang mencadangkan 
kerosakan DNA sebagai isyarat awal kesan sitotoksisiti EGCG terhadap sel. Kesimpulannya, dengan mengurangkan 
viabiliti sel dan mengaruh kerosakan DNA, EGCG berpotensi digunakan sebagai rawatan alternatif ke atas leukemia 
melalui tapak jalan selain kitaran sel dan kajian lanjutan mengenai mekanisma tindakan lain EGCG pada sel adalah 
disarankan.
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INTRODUCTION
Chronic myeloid leukemia (CML) is a hematological 
malignancy that occurs due to t(9;22)(q34;q11) translocation 
characterized by increased in proliferation of granulocytic 
cell lines with loss capacity to differentiate (Houshmand 
et al. 2019). The main cause of CML is due to the fusion 
of bcr/abl oncogene forming a Philadelphia chromosome 
which then encodes a chimeric Bcr/Abl protein with a 
constitutive activation of tyrosine kinase activity (Li et al. 
2012; Cao et al. 2014; Goker et al. 2014). Bcr/Abl fusion 
protein could affect cell proliferation and malignant 
transformation by activating different signal pathways or 
inducing uncontrolled transition of cell cycle.
Chemotherapy has been the first choice of treatment 
for those patients with advanced CML and Imatinib was 
approved as frontline CML management in 2001 as it 
inhibits the activity of tyrosine kinase. Since approved, 
Imatinib has been proven to be effective in achieving high 
remission rates and improving prognosis (Bhamidipati et 
al. 2013). However, this treatment always comes with 
toxicity and several adverse effects such as cardiac toxicity, 
hepatotoxicity, cutaneous toxicity, gynecomastia 
hypothyroidism, abnormal bone and mineral metabolism 
(Mughal & Schrieber 2010). Therefore, it is of high 
importance to find an alternative treatment for leukemia, 
which does not produce these adverse effects. 
EGCG, which is the most active catechin found in green 
tea has various biologic activities, including, apoptosis 
induction, cell cycle arrest, anti-proliferation and anti-
oxidation. EGCG was proven possessing this various 
biologic activities against various human cancer cell lines 
in several studies suggesting that it may be a promising 
anti-cancer agent (Otsuka et al. 1998; Lazaro et al. 2011; 
Stearns et al. 2011; Zhou et al. 2013; Goker et al. 2014). 
To further explore its anti-tumor effect especially regarding 
cell cycle progression and explore its mechanism, human 
chronic myeloid leukemia K562 cell line served as a model 
in our study.
This study aimed to determine the cytotoxic and 
genotoxic effect of EGCG in K562 cell line. This study also 
aimed to detect alteration in cell cycle distribution after 
treatment with EGCG in K562 cell line.
MATERIALS & METHODS
CELL CULTURE
Human chronic myeloid leukemia K562 cells (ATCC) were 
grown and maintained in IMDM medium supplemented 
10% fetal bovine serum (FBS) and 1% penicillin/
streptomycin.
CELL TREATMENT
Stock solution of EGCG (Sigma-Aldrich) at a concentration 
of 100 mg/mL was prepared in phosphate buffer saline 
(PBS) and stock solution of Imatinib mesylate (Nacalai 
Tesque)  at a concentration of 5 mg/mL as a positive control 
was prepared in distilled water. Both of the stock solutions 
were stored at -4˚C until use. Required concentrations (1-
100 μg/mL EGCG and 1-50 μg/mL Imatinib) were freshly 
prepared by diluting the stock solution in culture medium 
immediately before use. Twenty four hours after seeding, 
the cells were treated with appropriate concentration of 
EGCG and Imatinib for 48 hours in culture conditions 
(37°C, 5% CO2, 98% humidity). Control cells were 
incubated under the same conditions without any treatment.
CYTOTOXICITY ASSAY
Cytotoxic effects of EGCG and Imatinib against K562 cells 
were evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay following 
method by Mosmann (1983). Cells were seeded onto 96-
well microplates at a density of 1 × 105 cells per well and 
exposed to various concentrations of EGCG (3.125, 6.25, 
12.5, 25, 50 and 100 μg/mL) and Imatinib (1.5625, 3.125, 
6.25, 12.5, 25 and 50 μg/mL) for 48 hours. MTT solution 
(5 mg/mL) was added following incubation at a final 
concentration of 0.5 mg/mL and further incubated for 4 
hours. The supernatant was removed, and DMSO was added 
to dissolve the formed formazan crystal. The plate was 
further incubated for 15 minutes prior to measurement at 
570 nm with an ELISA plate reader (Bio-Rad, USA). Cell 
viability was calculated as follows:
CELL CYCLE ANALYSIS
Cell cycle analysis was performed by PI staining at IC10, 
IC25 and IC50 of EGCG following method from Zakaria et 
al. (2009). Imatinib was used as the positive control at IC25 
and IC50 value. 1 × 105 K562 cells were treated for 48 hours. 
After 48 hours, the cells are collected, centrifuged (2500 
rpm, 5 minutes, 4°C), fixed in 70% ethanol and then 
centrifuged again. Subsequently, cells were stained with 
500 µL of PI solution (BD Bioscience, USA) for 15 minutes 
at room temperature. Stained cells were analyzed using 
FACSCanto II flow cytometer (BD Bioscience, USA) 
installed with ModFit LT (Verity Software House).
% viability =  optical density of sample    
× 100%. 
optical density of control   
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ALKALINE COMET ASSAY
Alkaline comet assay was used to detect DNA damage [15] 
at IC10, IC25 and IC50 of EGCG treated cells. Imatinib was 
used as the positive control at IC25 and IC50 value. A total 
of 3 mL of K562 cells at 1 × 105 cells/mL was incubated 
for 24 hours and were then treated with EGCG and Imatinib. 
All cells were then incubated for 48 hours. Prior to 
incubation, cells were collected and centrifuged at 2500 
rpm for 5 minutes. The supernatant was discarded and this 
process was repeated. The low melting point agar (LMPA) 
and normal melting point agar (NMPA) (Sigma Aldrich, 
USA) were preheated until the agar melted. When the NMPA 
reached a temperature of 37°C, a total of 100 μL of NMPA 
was pipetted onto a frosted slide and a coverslip (50 mm 
x 22 mm) was placed on top of the slide. The coverslip 
was then taken out slowly after the agar hardened. Next, 
about 80 μL of LMPA was added into each sample tube on 
top of the prepared NMPA slide and a coverslip was placed 
slowly onto the two layers of gel. The coverslip was placed 
in a coplin jar filled with the lysing solution and cooled at 
4°C overnight before the slides were placed on the 
electrophoresis tank. Electrophoresis buffer was added into 
the tank to immerse the slide for 20 minutes. The 
electrophoresis process was carried out for 20 minutes at 
25 V and 300 mA after which the slides were rinsed with 
neutralizing buffer three times for every 5 minutes. The 
slides were then stained with 50 μL of ethidium bromide 
(Sigma Aldrich, USA) at 20 μg/mL. The single and isolated 
cell for every slide were analysed for any DNA damage 
under a fluorescent microscope (Biochrom ASYS,UK).
STATISTICAL ANALYSIS
All data were analysed by using SPSS Software Version 
22. All data were done in triplicate and were expressed as 
the mean ± S.E.M. from three different experiments. One-
way ANOVA and Tukey post hoc test were used to measure 
statistical differences between the mean in all experiments. 
The statistical difference was indicated with value p<0.05.
RESULTS
EGCG AND IMATINIB EXERT CYTOTOXICITY 
AGAINST CHRONIC MYELOID LEUKEMIA K562 
CELLS
As shown in Figure 1, a significant cytotoxic effect of EGCG 
and Imatinib in K562 human myeloid leukemia cells was 
noted. After exposed to EGCG for 48 hours, K562 cells 
showed a significant decreased (p<0.05) in viability with 
increasing concentration. Treatment with EGCG with the 
lowest dose at 3.125 μg/mL reduced the cell viability from 
96.43 ± 2.44 % to 37.23 ± 3.88 % at the highest dose (100 
μg/mL ) and the IC50 of the treatment is 50 ± 1.93 µg/mL. 
Treatment with Imatinib as positive control showed a 
significant decreased (p<0.05) in viability with increasing 
concentration as well. The cell viability with Imatinib 
reduced from 55.29 ± 0.34 % to 3.12±1.46 %. 
(a)
(b)
FIGURE 1. EGCG and Imatinib exerted cytotoxic effect on  
K562 human myeloid leukemia cell line. Percentage viability 
of a) EGCG and b) Imatinib following 48 hours treatment. 
IC10, IC25 and IC50 values for EGCG on K562 cells are 5 ± 2.44 
µg/mL, 10 ± 5.93 µg/mL and 50 ± 1.93 µg/mL respectively. 
Meanwhile, IC10, IC25 and Imatinib are 0.2 ± 0.0µg/mL, 
1 ± 0.34µg/mL and 2 ± 0.0 µg/mL respectively. Results 
are expressed as the means ±SEM of three independent 
experiments. An asterisk * indicates statistically a significant 
different from untreated control (p<0.05)
EFFECT OF EGCG AND IMATINIB ON CELL 
CYCLE DISTRIBUTION
Cell cycle analysis was performed to elucidate the 
involvement of cell cycle arrest in the EGCG mechanism 
of action. Following 48-hour treatment with the IC10, IC25 
and IC50 values of EGCG, G0/G1 population of the K562 
cells (23.44 ± 0.71 %, 22.74 ± 0.43 % and 18.53 ± 0.81 
%) was lower than that of the negative control (26.61 ± 
66
0.39 %). However, this reduction is insignificant (p>0.05) 
as compared to negative control. An insignificant (p>0.05) 
increase in the S phase population is noted as well. The 
cell number percentage of S phase increased from 57.35 ± 
1.52 % to 62.25 ± 0.57 %, 62.85 ± 0.50 % and 62.42 ± 1.1 
%, respectively. For G2/M population, the cells is lower 
in IC10, IC25 (14.31 ± 0.21 % and 14.41 ± 0.55 %) and 
higher in IC50 values of EGCG (19.84 ± 1.95 %) as compared 
to negative control (16.03 ± 1.26 %). As for the Imatinib, 
our result showed a high distribution of cells in G0/G1 
population and significant decreased (p<0.05) in G2/M 
population suggesting an arrest at S phase. Overall, this 
finding suggests that EGCG does not have a significant 
effect on the cell-cycle distribution of K562 cells (Figure 
2).
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FIGURE 2. Effect of EGCG and Imatinib on the cell cycle distribution of K562 cells. Histogram (a) represents cell cycle distribution 
by flow cytometry, and bar graph (b) represents the percentage of cells in every phase. Cells were exposed to IC10, IC25 and IC50 
values of EGCG for 48 hours and harvested. The cells were fixed and stained with propidium iodide and the DNA content was 
analyzed by flow cytometry. Results showed insignificant changes in cell cycle distribution with EGCG treatment as compared to 
negative control. Meanwhile, there is an arrest at S phase with Imatinib treatment. Results are expressed as the means ±SEM of 
three independent experiments
a Significant differences in cells distribution as compared to negative control (p<0.05)
b Significant differences in cells distribution as compared to positive control (p<0.05)
(b)
(a)
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EGCG INDUCED DNA DAMAGE IN K562 
CELLS
Figure 3 presented tail moment of K562 cells after treatment 
with EGCG at IC10, IC25 and IC50 values for 48 hours and 
Figure 4 presented percentage of DNA in tail after treatment 
with EGCG at IC10, IC25 and IC50 values for 48 hours. One-
way ANOVA analysis displayed a significant (p<0.05) 
increased of both K562 cell tail moment and percentage of 
DNA in tail when compared to the negative control (0.14 
± 0.02 A.U and 3.33 ± 0.38 %) which were 15.55 ± 1.55 
A.U, 26.69 ± 2.45 A.U, and 63.16 ± 4.2 A.U, and  14.55 ± 
1.10 %, 23.28 ± 1.51%, and 35.83 ± 1.75 %, respectively. 
The value of tail moment and percentage of DNA in tail 
increased as the concentration increased. The positive 
control, Imatinib at IC25 and IC50 exhibited significant 
increased (p<0.05) in the tail moment and  the percentage 
of DNA in tail of K562 cells at 23.02 ± 2.23 A.U and 51.63 
± 4.31 A.U. , and 22.22 ± 1.56 % and 29.60 ± 1.90 %, 
respectively.
FIGURE 3. Tail moment of K562 cells after 48 hours of 
treatment with EGCG and Imatinib. There is significant 
(p<0.05) increased in the tail moment at IC10, IC25 dan IC50 
values as compared to the negative control (0.14 ± 0.02 A.U) 
at 15.55 ± 1.55 A.U, 26.69 ± 2.45 A.U, and 63.16 ± 4.2 A.U 
respectively. Treatment with Imatinib showed significant (p < 
0.05)  increased in tail moment at IC25 and IC50 values at 23.02 
± 2.23 A.U and 51.63 ± 4.31 A.U as compared to the negative 
control. Results are expressed as the means ±SEM of three 
independent experiments. An asterisk * indicates statistically 
significantly different from untreated control (p<0.05)
FIGURE 4. Percentage of DNA in tail of K562 cells after 
48 hours of treatment with EGCG and Imatinib.  There is 
significant (p<0.05) increased in percentage of DNA in tail at 
IC10, IC25 dan IC50 values as compared to negative control (0.14 
± 0.02%) at 14.55 ± 1.10 %, 23.28 ± 1.51%, dan 35.83 ± 1.75 
% respectively. Treatment with Imatinib showed significant (p 
< 0.05)  increased in the tail moment at IC25 and IC50 values at 
22.22 ± 1.56% dan 29.60 ± 1.90 U as compared to the negative 
control. Results are expressed as the means ±SEM of three 
independent experiments. An asterisk * indicates statistically 
significantly different from untreated control (p<0.05)
DISCUSSION
The search for an alternative treatment in order to have a 
good diagnosis and prognosis of leukemia with specific 
treatment and less adverse effect has attracted great interest 
recently, particularly from natural products. Anti-leukemic 
agent from natural products and its derivatives are 
considered as more effective in achieving good prognosis 
(Dirsch et al. 1998; Lin et al. 2005; Jia et al. 2009; 
Abdellatef et al. 2010; Khan et al. 2010’ Qi et al. 2010; 
Choi et al. 2011). This study was using Epigallocatechin-
3-gallate (EGCG), a derivative extracted from green tea, to 
determine cytotoxic, genotoxic effect and cell cycle 
analysis against human myeloid leukemia K562 cells. 
In the present study, EGCG exerted a cytotoxic effect 
against K562 cells, as demonstrated by MTT assay (Figure 
1). Our result showed that EGCG reduced cell viability in 
a dose-dependent manner as compared to Imatinib 
Mesylate, positive control used in this study. These findings 
demonstrated that EGCG exerted an antiproliferative effect 
in parallel with the primary treatment of CML which is 
Imatinib mesylate. It supports the facts that suggesting the 
usage of EGCG as one of the anti-cancer agents (Singh et 
al. 2011; Yang et al. 2011).
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Cell cycle analysis was performed to investigate the 
possible events that occurred before cell death since our 
previous study concluded apoptosis as the primary mode 
of cell death in K562 after treated with EGCG. EGCG 
treatment decreased the G0/G1 and G2/M population in 
K562 cells. In addition, our result showed there is an 
increased in S phase population in K562 cells. However, 
these changes in these three phases are not significant as 
compared to negative control. This result suggests the 
possibility of a cell cycle arrest at S phase indicates there 
was a temporary arrest in the cell cycle due to DNA damage 
and with no specific mechanism the cell managed to 
progress through the next phases. In order to have further 
understanding of this occurrence, further research at the 
molecular level needs to be done particularly regarding the 
expression of protein regulators involved in modulation of 
the cell cycle. A study on the ethyl acetate extract of 
Dillenia suffruticosa reported a similar trend of cell cycle 
distribution in MCF-7, human breast cancer cells (Tor et 
al. 2014) and another study on the extract of Clinacantus 
nutans also showing similar trend in HeLa, cervical cancer 
cell line (Mohd Roslan et al. 2018). 
Cytotoxic effect induced by EGCG towards K562 cells 
may be caused by DNA damage and the detected 
genotoxicity might be the early mechanism of cell death 
via apoptosis. Alkaline comet assay was used to detect the 
genotoxic effect of the tested compound by measuring its 
DNA damage at a single cell that can be observed under a 
fluorescent microscope with a comet head (nucleus) and 
its tail (DNA fragments). In this study, the parameters used 
to determine the DNA damage are tail moment and 
percentage of DNA in tail. Among the frequently used 
comet parameters, the percentage of DNA in tail and tail 
moment could offer the most precise result for the degree 
of damage (Olive & Banath 2006).
In this study, increased in tail moment and percentage 
of DNA in tail were observed indicating there was induction 
of DNA damage by EGCG against K562 cells. DNA is the 
key target by most cytotoxic anticancer drugs. The anti-
cancer agent could act directly through reactive metabolites 
or indirectly through the incorporation into DNA nucleotide 
analogues or by blockade of DNA-metabolizing function 
such as DNA polymerase or topoisomerase (Roos & Kaina 
2013). Nonetheless, the mechanism and type of DNA lesion 
of K562 cells induced by EGCG need further investigation 
to truly understand the mechanism of DNA damage that 
leads to apoptosis.
In summary, our data show that the mechanism of 
anti-cancer exerted by EGCG is by decreasing the cell 
viability and inducing DNA damage, which then lead to 
apoptosis through a non-cell cycle specific pathway. This 
mechanism of inducing apoptosis through a non-cell cycle 
specific pathway is similar to the finding from a study by 
Tor et al. (2014). This study suggested that apoptosis occurs 
due to the modulation of gene through oxidative stress 
pathway (Tor et al. 2014).
CONCLUSION
Our study emphasized the involvement of cytotoxic and 
genotoxic effect of EGCG through non-cell cycle specific 
in inducing apoptosis. This preliminary study needs further 
attention in order to gain a full understanding of possible 
mechanisms of action of EGCG to strengthen its therapeutic 
value as a leukemia treatment. 
ACKNOWLEDGEMENT
The authors wish to thank the medical laboratory personnel 
for guidance and financial support from the Faculty of 
Health Sciences, Universiti Kebangsaan Malaysia.
CONFLICT OF INTEREST
The authors declared no potential conflict of interest with 
respect to the authorship and/or publication of this article.
REFERENCES
Abdellatef, E., Nassrallah, H. M. D. A. A., Aboul-Enein, 
K. M., El-Shemy, H. A., & Khalafalla, M. M. 2010. 
Antiproliferative action of moringa oleifera lam. root 
extracts in acute myeloid leukemia (AML) Cell Line. 
Journal of Experimental Sciences 1(8). 27-28.
Cao, J., Ren, L. L., Liu, J. W., Li, Yi. & Qu, H.Y. 2004. 
Gene expression spectra in human leukemia HL-
60 cells treated with EGCG. Mutation Research 
556:193-200.
Choi, Y. J., Yoon, J. H., Cha, S. W., & Lee, S. G. 
2011. Ginsenoside Rh1 inhibits the invasion and 
migration of THP-1 acute monocytic leukemia cells 
via inactivation of the MAPK signaling pathway. 
Fitoterapia 82(6): 911-919.
Dirsch, V. M., Gerbes, A. L., & Vollmar, A. M. (1998). 
Ajoene, a compound of garlic, induces apoptosis in 
human promyeloleukemic cells, accompanied by 
generation of reactive oxygen species and activation 
of nuclear factor κB. Molecular pharmacology 53(3): 
402-407.
Goker, B., Caliskan, C., Caglar, H. O., Kayabasi, C., 
Balci, T., Tepedelen, B. E.,Aygunes, D., Susluer, S. 
Y., Mutlu, Z., Gunell, N. S., Korkmaz, M., Saydam, 
G.,Gunduz, C. & Avci, C. B. 2014. Synergistic effect 
of ponatinib and epigallocatechin-3-gallate induces 
69
apoptosis in chronic myeloid leukemia cells through 
altering expressions of cell cycle regulatory 
genes. JBUON. 19(4): 992 -998.
Houshmand, M., Simonetti, G., Circosta, P., Gaidano, 
V., Cignetti, A., Martinelli, G., Saglio, G. & Gale, 
R.P. 2019. Chronic myeloid leukemia stem cells. 
Leukemia. 33: 1543-1556.
Khan, M., Giessrigl, B., Vonach, C., Madlener, S., 
Prinz, S., Herbaceck, I., Hölzl, C., Bauer, S., Viola, 
K. & Mikulits, W. 2010. Berberine and a Berberis 
lycium extract inactivate Cdc25A and induce 
α-tubulin acetylation that correlate with HL-60 cell 
cycle inhibition and apoptosis. Mutation Research/
Fundamental and Molecular Mechanisms of 
Mutagenesis 683(1): 123-130.
Li, L., Dai, H. J., Ye, M., Wang, S. L., Xiao, X. J., Zheng, 
J. & Chen, H. Y. 2012. Lycorine induces cell-cycle 
arrest in the G0/G1 phase in K562 cells via HDAC 
inhibition. Cancer Cell International 12: 49-54.
Lin, C. C., Kao, S. T., Chen, G. W., & Chung, J. G. (2005). 
Berberine decreased N acetylation of 2-aminofluorene 
through inhibition of N-acetyltransferase gene 
expression in human leukemia HL-60 cells. 
Anticancer research 25(6B): 4149- 4155.
Lopez-Lazro, M., Calderon-Montano, J. M., Burgos-
Moron, E. & Austin, C. A. 2011. Green tea contituents 
(-)-epigallocatechin-3-gallate (EGCG) and gallic 
acid induce topoisomerase I- and topoisomerase 
II-DNA complexes in cells mediated by pyrogallol-
induced hydrogen peroxide. Mutagenesis 1-10.
Mohd Roslan, S. N. F., Zakaria, Y. & Abdullah, H. 2018. 
Cytotoxicity of Clinacanthus nutans and mechanism 
of action of its fraction towards human cervical 
cancer cell line, HeLA. Jurnal Sains Kesihatan 
Malaysia 16(2): 39-50.
Mughal, T. I. & Schrieber, A. 2010. Principal long-term 
adverse effects of imatinib in patients with chronic 
myeloid leukemia in chronic phase. Biologics 4: 315-
323.
Olive, P. L. & Banath, J. P. 2006. The comet assay: a 
method to measure DNA damage in individual cells. 
Nature Protocols-Electronic Edition 1(1):23-29. 
Otsuka, T., Ogo, T., Eto, T., Asano, Y., Suganuma, M. & 
Niho, Y. 1998. Growth  inhibition of leukemic cells 
by (-)-epigallocatechin gallate, the main constituent 
of green tea. Life Sciences 63(16): 1397-1403
Qi, F., Li, A., Inagaki, Y., Gao, J., Li, J., Kokudo, N., Li, 
X.-K. & Tang, W. 2010. Chinese herbal medicines 
as adjuvant treatment during chemo-or radio-therapy 
for cancer. Biosci Trends 4(6): 297-307.
Qi, L. W., Wang, C. Z., & Yuan, C. S. (2010). American 
ginseng: potential structure–function relationship in 
cancer chemoprevention. Biochemical pharmacology 
80(7): 947-954.
Roos, W. P., & Kaina, B. 2013. DNA damage-induced cell 
death: from specific DNA lesions to the DNA damage 
response and apoptosis. Cancer letters 332(2): 237-
248.
Singh, B. N., Shankar, S. & Srivastava, R. K. 2011. Green 
tea catechin, epigallocatechin3-gallate (EGCG): 
Mechanisms, perspectives and clinical applications. 
Biomedical Pharmacology 82: 1807-1821.
Tor, Y. S., Latifah S. Y., Foo, J. B., Nurdin, A., Cheah, 
Y. K., Rasedee, A., Mustapha, U. I., Norsharina, I. 
& Maznah, I. 2014. Induction of apoptosis through 
oxidative stress-related pathways in MCF-7, human 
breast cancer cells, by ethyl acetate extract of Dillenia 
suffruticosa. BMC Complementary and Alternative 
Medicine 14(55): 1-12.
Yang, C. S., Wang, H., Li, G. X., Yang, Z., Guan, F. & 
Jin, H. 2011. Cancer prevention  by tea: Evidence 
from laboratory studies. Pharmacological Research 
64: 113-122.
Zhou, D. H., Wang, X., Yang, M., Shi, X., Huang, W. & 
Feng, Q. 2013. Combination of low concentration 
of(-)Epigallocatechin gallate(EGCG) and curcumin 
strongly suppresses the growth of non-small cell lung 
cancer in vitro and in vivo through causing cell cycle 
arrest. Int. J. Mol. Sci. 14: 12023-12036.
Elda Surhaida Latif
Siti Nurfarhanah Zahari
Asmah Hamid
Program of Biomedical Science
Center for Health and Applied Sciences
Faculty of Health Sciences
Universiti Kebangsaan Malaysia
Jalan Raja Muda Abdul Aziz, 
50300 Kuala Lumpur
MALAYSIA
